Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation

Gaurav Gupta, Karl L. Womer

Research output: Contribution to journalReview article

Abstract

The last several decades have witnessed a substantial decrease in the incidence of acute allograft rejection following kidney transplantation, although commensurate improvements in long-term graft function have not been realized. As a result, the primary focus of new immunosuppressive drug development has expanded to include ease of use and improved side effect profile, including reduced nephrotoxicity, in addition to the more traditional goal of improved short-term outcomes. A number of novel drugs are currently under investigation in Phase I, II, or III clinical trials, primarily to replace the nephrotoxic but highly effective calcineurin inhibitors. Belatacept is a humanized antibody that inhibits T cell costimulation and has shown encouraging results in multiple Phase II and III trials. This article reviews the mechanism of action of belatacept, as well as published and preliminary results of the Phase I-III clinical trials involving this novel immunosuppressive agent.

Original languageEnglish (US)
Pages (from-to)375-382
Number of pages8
JournalDrug Design, Development and Therapy
Volume4
DOIs
StatePublished - Dec 1 2010

    Fingerprint

Keywords

  • Graft rejection
  • Immunosuppression
  • Kidney transplantation
  • Post-transplant lymphoproliferative disease
  • T cell costimulation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this